Pathogenesis and Triazole Resistance in Aspergillus fumigatus: A Narrative Review Across the Host Immune Spectrum and One Health Context Authors: Tianfang Chen, Yelu Yao, Jianwu Chen, Huoyang Lv, Peng Nan Published: 2026 ABSTRACT AbstractThis narrative review explores triazole resistance and pathogenesis of Aspergillus fumigatus (A. fumigatus) under a unified One Health framework, integrating evidence across host immune spectrums, agricultural environmental selection pressures, veterinary aspergillosis and clinical antifungal management. We illustrate layered host-fungus immune interactions underlying distinct clinical aspergillosis phenotypes, and delineate core resistance mechanisms including cyp51-related target alterations, enhanced efflux pump activity, biofilm-mediated tolerance and adaptive stress response rewiring. Special emphasis is placed on cross-sector transmission pathways of azole-resistant A. fumigatus (ARAF) originating from agricultural ecosystems, as well as surveillance deficits and public health risks linked to animal intermediate hosts. Novel antifungal agents, such as olorofim, fosmanogepix, rezafungin, ibrexafungerp, and T-2307, along with targeted delivery and immunomodulatory adjunct therapies for resistant aspergillosis, are also summarized. Literature published 2020–2026 was retrieved from PubMed via Boolean search strategies, with supplementary manual screening of landmark reference lists to include pivotal earlier studies. Only peer-reviewed original studies, epidemiological surveillance reports, and review articles with complete clinical or experimental datasets were incorporated following rigorous screening. Most studies discuss clinical or agricultural resistance separately, lacking integrated analyses covering human, animal, and environmental dimensions. Major knowledge gaps persist regarding horizontal gene transfer of resistance mutations, cross-species transmission chains, and translational applications of environmental monitoring data. This review summarizes existing research bottlenecks and proposes integrated multi-sector prevention and control strategies from a One Health perspective to curb the growing threat of triazole-resistant aspergillosis. Introduction A. fumigatus, a saprophytic fungus ubiquitous in soil and decomposing organic matter, poses a triple threat to human health.1 First, its airborne conidia (2–3 μm) are small enough to evade upper airway defenses and penetrate deep into the lungs, establishing a portal of entry that makes inhalation a near-daily occurrence for the general population.2 Second, within healthcare settings, environmental reservoirs, including heating, ventilation, and air conditioning (HVAC) systems, construction dust, and even medical device biofilms, facilitate cross-transmission to high-risk patients in ICUs and transplant units, where invasive aspergillosis carries mortality rates of 40–50%.3–5 Third, the One Health framework links the environment, animals and humans. Agricultural settings serve as key reservoirs of triazole resistance.6 Heavy long-term fungicide use in Europe and China drives resistance development, with nearly 80% resistant isolates recovered from greenhouses in Yunnan, China.7 Cross-border flower bulb trade facilitates intercontinental spread; over half of tulip imports carry strains genetically closely related to European resistant isolates.8 Resistant environmental fungi have been identified on European farms and in zoo settings, and most infected animals have no azole exposure, supporting environmental spillover to animal hosts.9 This convergence of environmental ubiquity, clinical vulnerability, and cross-sectoral resistance has led the WHO to classify A. fumigatus as a high-risk “critical priority” fungal pathogen alongside Cryptococcus neoformans and Candida auris.10 Host immunity forms a continuous spectrum that critically shapes the adaptive evolution of A. fumigatus. In immunocompetent individuals, inhaled conidia are typically cleared rapidly via mucociliary clearance and phagocytosis by alveolar macrophages, making clinical infection uncommon.11 In contrast, among patients with severe immunodeficiency, such as those with persistent neutropenia, hematopoietic stem cell transplantation, or high-dose immunosuppressive therapy, hyphae can invade blood vessels directly, leading to hematogenous dissemination and the highly lethal condition invasive aspergillosis.3 Crucially, intermediate immune states, including those underlying chronic pulmonary aspergillosis or allergic bronchopulmonary aspergillosis, typically involve mild immunodeficiency or local immune dysregulation. While unable to eradicate the pathogen completely, these conditions exert sustained selective pressure. This state of chronic colonization provides a temporal window for the accumulation of mutations in resistance and virulence genes, alongside phenotypic selection, thereby driving the coevolution of virulence and drug resistance.12 Consequently, the host immune gradient not only determines clinical outcomes but also acts as a core driver of this coevolution through the cycle of stress, adaptation, survival, and transmission. Triazole antifungals remain the cornerstone of aspergillosis management due to their oral bioavailability and broad-spectrum activity against A. fumigatus.13 They target Cyp51A, disrupting ergosterol biosynthesis and membrane integrity.14 However, the global detection rate of triazole-resistant A. fumigatus continues to rise, and the true burden of resistance remains substantially underestimated because susceptibility testing is often omitted in non-invasive disease.15 Resistance arises via cyp51A target-site mutations and efflux pump overexpression, but these mechanisms are not confined to the clinic. Environmentally selected resistant strains recovered from azole-naive patients underscore the overlap in resistance mechanisms between agricultural and clinical spheres.16 Guided by the immune gradient framework, this review first elucidates the pathogenic characteristics of A. fumigatus across distinct host immune niches. It then delineates the mechanisms of triazole resistance, including target-site mutations, efflux pump overexpression, biofilm-mediated resistance, and stress signaling pathway activation, and their environmental and clinical drivers. Finally, adopting a One Health perspective, the review outlines a cross-interface research framework for the coevolution of virulence and drug resistance, and surveys novel therapeutic and integrated control strategies. The aim is to provide a theoretical reference and call for interdisciplinary integration of human-environment-fungal data to guide future efforts against drug-resistant aspergillosis. Methods Search Strategy Literature searches were performed in PubMed. Primary electronic screening prioritized peer-reviewed articles published between 2020 and 2026 to capture up-to-date epidemiological surveillance data, molecular resistance mechanisms, and novel findings regarding antifungal therapies. Boolean search terms were applied to cover core themes, including the pathogenesis and infection spectrum of A. fumigatus, molecular mechanisms of triazole resistance, host–fungal immune crosstalk, environmental resistance reservoirs driven by agricultural fungicides, veterinary aspergillosis, animal-derived resistant isolates, and cross-sector epidemiological evidence within a One Health framework. Following database retrieval, reference lists of landmark epidemiological studies and authoritative reviews were manually screened to identify key foundational papers published before 2020 as complementary evidence. Inclusion and Exclusion Criteria Eligible publications included original experimental studies, epidemiological surveillance investigations, clinical case series, and peer-reviewed narrative or systematic reviews focusing on triazole resistance in A. fumigatus from a One Health perspective. Studies were required to be written in English, with full-text accessibility, and report original experimental or population-level data covering at least one domain: human clinical infection, agricultural environmental exposure, or veterinary animal infection. Exclusion criteria were as follows: conference abstracts lacking comprehensive data analysis, studies exclusively investigating non-Aspergillus fungal pathogens, and duplicated datasets. Literature Screening Process All retrieved literature records were first screened by titles and abstracts to remove irrelevant documents and repeated entries; remaining potentially eligible manuscripts underwent full-text evaluation against the above eligibility rules. Quality Appraisal and Risk of Bias This study adopted a narrative synthesis design, and no standardized quantitative appraisal tools (eg, JBI, MMAT, CASP checklists) were used to score included articles. Instead of relying on unified scoring systems, we thoroughly read each full text to comprehensively assess its methodological rigor, clarity of study outcomes, and potential bias risk. All these evaluations were fully incorporated into the integrated analysis of literature evidence throughout this review. Mechanisms of A. fumigatus Pathogenesis Across Aspergillosis Types Aspergillosis refers to a spectrum of clinical syndromes caused by Aspergillus species, most commonly A. fumigatus, ranging from asymptomatic airway colonization to life-threatening invasive disease. The clinical phenotype is largely determined by two key factors: the host’s immune status and the anatomical site of infection. In immunocompetent individuals, inhaled conidia are rapidly cleared through integrated innate and adaptive immune mechanisms (Figure 1A).17 Mucociliary transport, opsonization, and phagocytosis by alveolar macrophages constitute the frontline defense, while adaptive immune responses reinforce fungal elimination and preserve immune homeostasis.17 By contrast, defective or dysregulated immunity predisposes to distinct forms of aspergillosis. Allergic and colonizing phenotypes typically arise in hosts with mild immune impairment or underlying pulmonary comorbidities (Figure 1B).18 Chronic pulmonary aspergillosis develops when host immunity is restricted yet fails to eradicate, resulting in fungal persistence (Figure 1C).19 In severely immunocompromised patients, uncontrolled hyphal growth leads to angioinvasion, thrombosis, tissue necrosis, and life-threatening hematogenous dissemination, defining invasive aspergillosis (Figure 1D). Figure 1Clinical spectrum of Aspergillus fumigatus diseases across different host immune statuses. (A) Immunocompetent host: Coordinated innate and adaptive immune responses clear inhaled spores, typically preventing disease. (B) Partially intact immunity: In the context of local dysregulation or structural defects, this status may lead to allergic bronchopulmonary aspergillosis (ABPA) (characterized by mucus obstruction, depicted as broad white markings) or non-invasive colonizing aspergillosis, such as aspergilloma (saprophytic growth within pre-existing pulmonary cavities). These two conditions are distinct clinical entities but are presented together to illustrate the continuum of host immune status. (C) Mild immunodeficiency: Characterized by a slow, progressive infection, leading to chronic pulmonary aspergillosis. Pre-existing pulmonary cavities represent a major predisposing risk factor for the development of chronic pulmonary aspergillosis. (D) Severe immunodeficiency: Predisposes to invasive aspergillosis, an often-fatal condition characterized by hyphal invasion and angioinvasion, which may disseminate to multiple organs (eg, brain, liver, kidneys).A medical infographic with four panels labeled A to D, illustrating aspergillosis progression based on immune status. Panel A, titled ′Immunocompetent Host′, shows healthy lungs with ′Spore Clearance No Disease′. An inset box displays ciliated cells, lumen and alveolar macrophage. Panel B, ′Partially Intact Immunity′, depicts lungs with ′ABPA (mucus obstruction, type 2 inflammation) Aspergilloma (cavity colonization)′. Panel C, ′Mild Immunodeficiency′, shows lungs with ′Chronic Aspergillosis′. Panel D, ′Severe Immunodeficiency′, illustrates lungs with ′Invasive Aspergillosis (Fatal)′, featuring a zoom box of hyphal invasion affecting the brain, liver and kidney. Each panel has a distinct colored header bar, emphasizing the progression from left to right, highlighting how immune status influences disease form.Infographic: aspergillosis stages by immunity spore clearance, ABPA, chronic, invasive. Clinical spectrum of Aspergillus fumigatus diseases across different host immune statuses. (A) Immunocompetent host: Coordinated innate and adaptive immune responses clear inhaled spores, typically preventing disease. (B) Partially intact immunity: In the context of local dysregulation or structural defects, this status may lead to allergic bronchopulmonary aspergillosis (ABPA) (characterized by mucus obstruction, depicted as broad white markings) or non-invasive colonizing aspergillosis, such as aspergilloma (saprophytic growth within pre-existing pulmonary cavities). These two conditions are distinct clinical entities but are presented together to illustrate the continuum of host immune status. (C) Mild immunodeficiency: Characterized by a slow, progressive infection, leading to chronic pulmonary aspergillosis. Pre-existing pulmonary cavities represent a major predisposing risk factor for the development of chronic pulmonary aspergillosis. (D) Severe immunodeficiency: Predisposes to invasive aspergillosis, an often-fatal condition characterized by hyphal invasion and angioinvasion, which may disseminate to multiple organs (eg, brain, liver, kidneys). Allergic Bronchopulmonary Aspergillosis (ABPA) Allergic Bronchopulmonary Aspergillosis (ABPA) is an allergic pulmonary disorder triggered by hypersensitivity to A. fumigatus. It primarily occurs in individuals with asthma or cystic fibrosis, who often exhibit impaired local airway clearance or structural lung defects despite their largely intact systemic immunity.20 The pathogenesis of ABPA centers on persistent fungal colonization and a dysregulated Th2 immune response.21 Spore germination activates airway epithelial cells to release alarmins (IL-25, IL-33, TSLP); IL-33 stimulates type 2 innate lymphoid cells (ILC2s) to secrete IL-5 and IL-13. Epithelial cells and dendritic cells recognize fungal patterns via pattern recognition receptors, with epithelial-derived cytokines regulating DC maturation and antigen presentation, ultimately inducing naïve T-cell differentiation into activated Th2 cells.22 ILC2s and Th2 cells release IL-4, IL-5, and IL-13, driving IgE production, eosinophil recruitment, and mucus hypersecretion.23 Eosinophils contribute to tissue damage via Charcot-Leyden crystal formation and extracellular DNA traps, which immobilize the fungus without killing it, perpetuating inflammation and structural damage. These processes result in airway inflammation, bronchiectasis, and mucus plugging (Figure 2). Collectively, these findings reveal a dynamic interplay among Aspergillus sensitization, type 2 airway inflammation, and mucus plug formation. Notably, this pathological cascade may initiate during the pre-clinical phase of Aspergillus sensitization, driving progression toward a refractory phenotype and providing a rationale for early intervention.24 Figure 2Pathogenic mechanisms of Allergic Bronchopulmonary Aspergillosis (ABPA) driven by Aspergillus fumigatus. Arrows indicate direction of signal transduction or cellular migration. A. fumigatus airway colonization triggers epithelial cells to release alarmins (IL-25, IL-33, TSLP); IL-33 activates type 2 innate lymphoid cells (ILC2s), while fungal pathogen-associated molecular patterns (PAMPs) drive dendritic cell (DC)-mediated CD4⁺ Th2 cell activation. ILC2s and Th2 cells secrete type 2 cytokines: IL-4 promotes IgE production, IL-13 induces goblet cell hyperplasia and excessive mucus secretion, and IL-5 expands eosinophils. Activated eosinophils form extracellular traps (EETs) that immobilize fungi, contributing to tissue damage. These processes collectively lead to ABPA-related pathologies: airway inflammation, bronchiectasis, and mucous plugging.Scientific schematic of a lung airway showing how inhaled Aspergillus spores interact with the airway lining and immune cells. At the top, fungal elements contact epithelial cells and are sensed by pattern-recognition receptors; nearby labels indicate fungal PAMPs. The epithelium releases mediators (IL25, IL33, TSLP) that stimulate an ILC2 cell, while a dendritic cell presents signals to activate a CD4+ T cell into a Th2 phenotype; an alveolar macrophage is also depicted. Downstream, a central type 2 cytokines release node branches to IL4, IL13 and IL5 outcomes: IL4 drives IgE production, IL13 promotes goblet cell hyperplasia and increased mucus and IL5 recruits and expands eosinophils. On the right, eosinophils become activated and form extracellular traps (EETs) shown in an inset. Along the left margin, three circular callouts summarize clinical consequences: airway inflammation, bronchiectasis and mucous plugging. Arrows throughout indicate signaling and cell movement across the airway surface.Flowchart of fungal-triggered type 2 immunity in the lung leading to mucus plugs and airway damage. Pathogenic mechanisms of Allergic Bronchopulmonary Aspergillosis (ABPA) driven by Aspergillus fumigatus. Arrows indicate direction of signal transduction or cellular migration. A. fumigatus airway colonization triggers epithelial cells to release alarmins (IL-25, IL-33, TSLP); IL-33 activates type 2 innate lymphoid cells (ILC2s), while fungal pathogen-associated molecular patterns (PAMPs) drive dendritic cell (DC)-mediated CD4⁺ Th2 cell activation. ILC2s and Th2 cells secrete type 2 cytokines: IL-4 promotes IgE production, IL-13 induces goblet cell hyperplasia and excessive mucus secretion, and IL-5 expands eosinophils. Activated eosinophils form extracellular traps (EETs) that immobilize fungi, contributing to tissue damage. These processes collectively lead to ABPA-related pathologies: airway inflammation, bronchiectasis, and mucous plugging. Genetic susceptibility contributes to ABPA risk.25 Only a subset of patients with asthma develop ABPA under identical environmental exposures.26 For instance, HLA class II molecules DR2 and DR5 promote Th2 activation via preferential presentation of A. fumigatus antigens.20 CFTR gene mutations, causative of cystic fibrosis, are observed in some non-CF ABPA patients, suggesting that epithelial dysfunction may indirectly enhance type 2 inflammation.27 The CARD9S12N polymorphism may exacerbate Th2-mediated airway inflammation via macrophage signaling pathways, experimentally validated in patient-derived cells4,28 (Figure 2). Although these genetic variants differ in origin, they collectively point toward excessive amplification of type 2 inflammation as a central pathogenic node. Nevertheless, the relative contribution of each variant and its potential synergistic interactions remain poorly defined. Future integration of polygenic risk scoring with functional validation may facilitate earlier identification of high-risk individuals and enable more precisely tailored therapeutic strategies based on individual genetic background. In addition to host genetic factors, fungal virulence determinants also interact with the airway microenvironment to collectively drive the progression of ABPA.29 On the one hand, intrinsic fungal regulatory factors directly influence allergenic and pathogenic capacity. The transcription factor SltA serves as a key virulence regulator; knockout of sltA attenuates A. fumigatus virulence by downregulating expression of the major allergen Asp f1. Furthermore, the expression level of the alkaline protease Alp1 (Asp f13) correlates with asthma severity, impaired lung function, and corticosteroid dosage, and its detectability in the airways of asthmatic patients positions it as a promising biomarker and therapeutic target for asthma.30 On the other hand, the airway microenvironment further amplifies these virulence effects. For instance, elevated airway iron levels, a common finding in patients with cystic fibrosis, directly stimulate the fungus to secrete increased quantities of proteases, thereby exacerbating type 2 inflammation.31 The disruption of pulmonary tissue by proteases further impairs airway clearance, facilitating persistent fungal colonization and thereby exacerbating tissue injury. Collectively, fungal virulence factors and the aberrant airway microenvironment reinforce each other, establishing a vicious cycle. This implies that simply inhibiting downstream protease activity or relying exclusively on conventional antifungal therapy may prove insufficient within an iron-overloaded inflammatory milieu. Instead, strategies aimed at restoring microenvironmental homeostasis or disrupting fungal iron-sensing signaling cascades may represent more promising interventional approaches. Aspergilloma Aspergilloma is a spherical lesion composed of fungal hyphae, spores, necrotic tissue debris, and mucus that forms within pre-existing pulmonary cavities. It arises primarily from colonization by Aspergillus species, notably A. fumigatus, in cavities resulting from conditions such as healed tuberculosis or bronchiectasis.21,31 Its hallmark diagnostic feature is the confinement of the fungal ball within the pre-existing cavity lumen without invasive growth into the adjacent pulmonary parenchyma.32 This characteristic indicates that the physical barrier of the cavity microenvironment, together with the local immune response, restricts fungal invasion but fails to achieve complete eradication. Mechanistically, current evidence derives largely from in vitro studies or invasive aspergillosis models. These findings suggest that A. fumigatus may mediate initial adhesion via the hydrophobin RodA, adapt to the hypoxic cavity environment through the SrbA hypoxia response pathway and HapX-regulated iron acquisition systems, and facilitate hyphal extension by secreting proteases that degrade the extracellular matrix.33–35 However, direct in situ evidence for these molecular events within human aspergilloma cavity tissue remains lacking. Therefore, caution is warranted when extrapolating findings from in vitro or invasive infection models to the encapsulated, hypoxic microenvironment of an aspergilloma. Fungal metabolic states and virulence gene expression profiles may differ fundamentally across distinct disease contexts. With respect to host immunity, patients with aspergilloma typically possess broadly intact immune function. This suggests that the long-term maintenance of an aspergilloma reflects not a complete failure of immune clearance, but rather a dynamic equilibrium between physical containment and low-grade chronic inflammation. Histopathologically, tuberculous cavities are characterized by lymphocytic and plasma cell infiltration accompanied by collagen deposition.36 However, whether cavities harboring Aspergillus fungal balls exhibit the same inflammatory pattern remains unclear. Therefore, future studies employing spatial transcriptomics or multiplex immunohistochemistry on surgically resected aspergilloma specimens may be needed to define the characteristics of the local immune microenvironment. Elucidating these features will enhance our understanding of fungal survival strategies under the combined constraints of host immune pressure and physical barriers, thereby offering new insights into the biological nature of aspergilloma as a distinct infectious state. Based on current clinical evidence, oral triazole therapy remains the preferred option for surgically unresectable lesions.37 Prolonged administration of triazoles within the hypoxic cavity microenvironment may alter fungal metabolic states and exert selective pressure, thereby favoring the emergence of drug-resistant A. fumigatus strains. Consequently, exploring strategies such as intermittent dosing, local drug delivery, or combined microenvironment-targeted interventions may help delay the development of resistance. Chronic Aspergillosis Chronic aspergillosis does not arise from incidental fungal colonization, but results from long-term interplay between impaired host immune surveillance and persistent stimulation by A. fumigatus. Available evidence indicates that such chronic infections, with a duration of more than 3 months, predominantly occur in individuals with structural lung disease or mild immune compromise.18,32,38,39 Regarding immunopathogenesis, iatrogenic factors such as prolonged low-dose glucocorticoid therapy play a pivotal role in the development of chronic aspergillosis by disturbing the balance between innate and adaptive immunity. Specifically, glucocorticoid-mediated inhibition of the NF-κB pathway directly impairs NADPH oxidase-dependent fungicidal activity of neutrophils and blocks the formation of neutrophil extracellular traps and the initiation of Th1-type immune responses.40,41 This immune deviation prevents complete fungal clearance while retaining partial control over dissemination, shifting acute inflammation toward a chronic fibrotic process characterized by incomplete elimination and sustained tissue injury. Iatrogenic factors do not fully account for the spectrum of chronic pulmonary aspergillosis. Chronic pulmonary aspergillosis exhibits substantial clinical and immunological heterogeneity, indicating that simple immunosuppression cannot fully account for its pathogenesis. Studies on the cavitary subtype (CCPA) have revealed intrinsic links between host genetic background and defective innate immune sensing. Polymorphisms in pattern recognition receptors, including TLR1 and CLEC7A, downregulate basal expression of TLR3 and TLR10, and upregulate TREM1 expression on macrophages, collectively forming a molecular network associated with altered immune response thresholds and dysregulated local microenvironment.42 In addition, approximately 58% of CPA patients present with lymphopenia, and distinct immune phenotypes correlate with specific underlying lung disorders. Reduced CD19 levels are associated with sarcoidosis and emphysema, whereas decreased CD3 levels correlate with cavitary lesions.43 However, it remains unclear whether these immunophenotypic changes drive disease progression or represent secondary consequences of chronic inflammation. Prolonged antifungal therapy for chronic aspergillosis exerts strong drug-induced selective pressure. In the setting of impaired immune clearance, genetic adaptations of the fungus to the host environment frequently lead to treatment failure and progression to refractory invasive disease. Future therapeutic strategies should therefore aim not only to optimize antifungal regimens but also to explore adjunctive immunomodulatory approaches tailored to specific immune defects. For instance, IFN-γ supplementation to restore protective immunity in patients with CPA has gained attention. Preliminary observations indicate that adjunctive IFN-γ therapy reduces acute exacerbations and hospitalizations in refractory CPA, and a randomized feasibility trial is currently underway (NCT05653193). In addition, biologic agents targeting pathways such as upstream TSLP, for example, tezepelumab, offer alternative avenues for correcting lymphocyte subset dysfunctions. However, the optimal patient selection and treatment regimens for these strategies remain to be defined. More importantly, a deeper understanding of the complex pathogenesis of CPA will provide a critical foundation for multi-target drug discovery. Enhancing host-mediated fungal clearance while developing multi-target interventions against fungal adaptive mechanisms could shorten antifungal treatment duration, reduce drug exposure, and ultimately slow the emergence of resistance at its source. Invasive Aspergillosis Invasive aspergillosis is a life-threatening infection caused by Aspergillus species, most commonly A. fumigatus, and characterized by angioinvasion and hematogenous dissemination.44 The development of invasive aspergillosis does not result from a simple absence of immune defense but rather from the interaction between specific immune defects and corresponding virulence mechanisms of A. fumigatus. Host immune defects exhibit marked clinical heterogeneity. Bone marrow failure induced by chemotherapy for acute myeloid leukemia leads to profound neutropenia. In contrast, recipients of allogeneic hematopoietic stem cell transplantation experience additional suppression of T-cell function as a consequence of the conditioning regimen, resulting in a dual immunological deficit.45,46 Thus, the pattern of immune impairment differs according to the underlying etiology. The pathogenic contribution of different A. fumigatus virulence factors depends on the host’s immune background. Gliotoxin, for instance, facilitates immune evasion by disrupting PtdIns(3,4,5)P3 metabolism in macrophages.2 However, gene knockout experiments reveal that its pathogenic necessity varies dynamically with the level of residual host immunity. In hosts that retain partial innate immune function, gliotoxin serves as a core determinant of fungal invasiveness. In profoundly neutropenic hosts, however, alternative virulence pathways can still drive lethal infection even in the absence of this toxin.47 This observation suggests that therapeutic strategies targeting a single virulence factor may exhibit markedly different efficacy depending on the host’s immune status. In addition, adaptation of A. fumigatus to host nutritional immunity also contributes to its pathogenic process. The fungus can acquire iron from the host by secreting siderophores such as ferrirhodin. Clinical studies have identified iron overload in hematopoietic stem cell transplant recipients as a significant risk factor for invasive aspergillosis.47–49 Regarding zinc homeostasis, the transcription factor ZafA participates in zinc uptake, iron metabolism, and oxidative stress responses through the regulation of downstream gene networks. zafA knockout strains exhibit growth defects, and exogenous zinc chelators similarly inhibit fungal growth. Because ZafA and its downstream target ZrfC are fungal-specific proteins, their potential value as therapeutic targets has attracted considerable attention.50–54 The pathogenesis of IA is not merely immune compromise leading to infection, but rather a complex interplay in which the fungus adjusts its virulence in response to host immunity. Risk assessment should therefore move beyond broad immune categorization toward precise stratification by specific pathway impairment. Antivirulence strategies must consider residual host immunity, while modulation of nutritional immunity may offer adjunctive opportunities. To date, siderophore-mediated iron acquisition has been validated in clinical isolates and animal models, whereas gliotoxin, though confirmed as a virulence factor, exhibits host immune status-dependent pathogenicity. Host immune status-guided antivirulence approaches remain an exploratory frontier. Mechanisms of Triazole Resistance in A. fumigatus A. fumigatus exhibits broad pathogenicity, and its clinical management relies heavily on antifungal therapy. The pathogenic forms discussed above correspond to high-risk scenarios for resistance emergence. Triazoles, including itraconazole, voriconazole, posaconazole, and isavuconazole, are the primary agents for treating invasive aspergillosis.55 These drugs target the Cyp51A enzyme, which catalyzes the 14α-demethylation of lanosterol to ergosterol, a key step in sterol biosynthesis.14 Ergosterol is critical for fungal cell membrane integrity and fluidity, and is essential for growth and survival.56 Triazoles inhibit ergosterol synthesis by binding to the heme iron in the Cyp51A active site, forming a stable complex that blocks lanosterol demethylation14,57 (Figure 3A and B). This inhibition causes accumulation of upstream intermediates (eg, lanosterol, 14α-methylated sterols)58 (Figure 3C). The resulting metabolic disruption, mediated by toxic sterol accumulation and ergosterol depletion, leads to cell growth arrest (Figure 3D). Figure 3Mechanism of action of triazole antifungal drugs via inhibition of ergosterol biosynthesis. (A) Binding: Triazoles specifically bind to the active site of the cytochrome P450 enzyme CYP51 (lanosterol 14-α-demethylase). (B) Inhibition: Inhibition of Cyp51 blocks demethylation of lanosterol, an essential step in ergosterol synthesis. (C) Accumulation: This blockade leads to toxic accumulation of lanosterol and other methylated sterol precursors. (D) Consequences: The resulting ergosterol deficiency and precursor accumulation compromise membrane fluidity, stability, and function, ultimately leading to fungal growth inhibition and may culminate in cell death.Panel A: Triazole drugs bind to the heme iron cofactor of Cyp51, labeled as Lanosterol 14-alpha-demethylase (P450), shown with a cell membrane and ergosterol. Panel B: Inhibition of Lanosterol 14-alpha-demethylase blocks ergosterol synthesis, indicated by a red X over ′synthesis′. Panel C: Cyp51 blockade causes lanosterol accumulation and buildup of toxic 14-alpha-methylated sterol intermediates. Panel D: Ergosterol depletion and toxic sterol accumulation disrupt cell membrane integrity, shown by a distorted membrane and a downward arrow. Each panel is part of a 2x2 grid, illustrating the stepwise mechanism of action of triazole antifungal drugs.Four-panel diagram illustrating triazole inhibition of ergosterol synthesis in a 2x2 grid. Mechanism of action of triazole antifungal drugs via inhibition of ergosterol biosynthesis. (A) Binding: Triazoles specifically bind to the active site of the cytochrome P450 enzyme CYP51 (lanosterol 14-α-demethylase). (B) Inhibition: Inhibition of Cyp51 blocks demethylation of lanosterol, an essential step in ergosterol synthesis. (C) Accumulation: This blockade leads to toxic accumulation of lanosterol and other methylated sterol precursors. (D) Consequences: The resulting ergosterol deficiency and precursor accumulation compromise membrane fluidity, stability, and function, ultimately leading to fungal growth inhibition and may culminate in cell death. In recent years, the increasing prevalence of triazole-resistant A. fumigatus has posed significant clinical challenges. Resistance emergence is driven by multiple factors: the expanding immunosuppressed population, prolonged clinical triazole use, and notably, the widespread agricultural use of azole fungicides (eg, tebuconazole) that structurally resemble medical triazoles. Environmentally resistant strains can enter healthcare settings via airborne transmission, leading to clinically relevant cross-resistance and contributing to elevated treatment failure and mortality in invasive aspergillosis.59 The underlying resistance mechanisms, including key gene mutations, metabolic adaptations, and enhanced efflux pump activity, are discussed in detail in the following sections. Gene Mutation Triazole resistance in A. fumigatus is mainly mediated by mutations and overexpression of the cyp51A gene, which encodes lanosterol 14α-demethylase (Cyp51), the target of triazole antifungal agents.60 The resistance mechanisms can be divided into two categories. First, gene mutations alter the structure of the target enzyme and reduce its binding capacity to drugs. Second, gene overexpression increases the synthesis of the target enzyme to counteract the inhibitory effect of drugs (Figure 4A). These two mechanisms are not mutually exclusive but often coexist in clinical drug-resistant strains, collectively contributing to elevated resistance levels. Figure 4Multiple mechanisms synergistically mediate Aspergillus fumigatus resistance and tolerance to triazole antifungals. Solid arrows show signaling, development, and transmission; dashed arrows mark environmental conidial spread. (A) Target-site mutations in cyp51A/cyp51B weaken triazole binding, relieving inhibition of ergosterol synthesis and conferring target-mediated resistance. The F390L variant within the sterol-sensing domain of Hmg1 confers robust azole resistance via a sterol metabolic bypass independent of cyp51A. (B) Enhanced drug efflux: Overexpression of ABC and MFS transporters actively pumps triazole antifungals out, lowering intracellular concentration. (C) Biofilm and microenvironment-induced tolerance: Aspergillus fumigatus biofilms progress through three stages: initial, immature, and mature. Increasing structural complexity, extracellular matrix (ECM) production, and hypoxia within the biofilm drive high expression of the Mdr4 efflux pump and a shift to hypoxic metabolism, collectively contributing to triazole tolerance. (D) Integrated stress response: Synergistic activation of CWI, HOG, calcineurin, and TOR pathways remodels cell wall and membrane homeostasis, establishing a layered defense. (E) Widespread agricultural azole use selects for resistant A. fumigatus in the environment. Resistant conidia may colonize livestock and companion animals (sentinel hosts), but direct animal-to-human transmission has not been established; environmental spread to clinical settings occurs via airborne conidia.The diagram illustrates multiple mechanisms of triazole resistance in Aspergillus fumigatus. Section A shows gene mutations, including cyp51A and cyp51B mutations, with specific point mutations like TR34/L98H and F390L in hmg1. Section B depicts efflux pump overexpression, highlighting ABC and MFS transporters actively pumping out triazoles, with mdrA genes involved. Section C describes biofilm development stages: initial, immature at 12 hours and mature at 24 hours, with increased Mdr4 expression and hypoxia contributing to tolerance. Section D outlines key signaling pathways, including Afwsc1, Rho1, MpkA and others, leading to antifungal tolerance through Crz1-dependent genes. Section E illustrates environmental factors, such as tebuconazole spray and spread via livestock and clinical settings, contributing to resistance development.Triazole resistance in A. fumigatus: gene mutations, efflux pumps, biofilms, signaling and environment. Multiple mechanisms synergistically mediate Aspergillus fumigatus resistance and tolerance to triazole antifungals. Solid arrows show signaling, development, and transmission; dashed arrows mark environmental conidial spread. (A) Target-site mutations in cyp51A/cyp51B weaken triazole binding, relieving inhibition of ergosterol synthesis and conferring target-mediated resistance. The F390L variant within the sterol-sensing domain of Hmg1 confers robust azole resistance via a sterol metabolic bypass independent of cyp51A. (B) Enhanced drug efflux: Overexpression of ABC and MFS transporters actively pumps triazole antifungals out, lowering intracellular concentration. (C) Biofilm and microenvironment-induced tolerance: Aspergillus fumigatus biofilms progress through three stages: initial, immature, and mature. Increasing structural complexity, extracellular matrix (ECM) production, and hypoxia within the biofilm drive high expression of the Mdr4 efflux pump and a shift to hypoxic metabolism, collectively contributing to triazole tolerance. (D) Integrated stress response: Synergistic activation of CWI, HOG, calcineurin, and TOR pathways remodels cell wall and membrane homeostasis, establishing a layered defense. (E) Widespread agricultural azole use selects for resistant A. fumigatus in the environment. Resistant conidia may colonize livestock and companion animals (sentinel hosts), but direct animal-to-human transmission has not been established; environmental spread to clinical settings occurs via airborne conidia. Multiple cyp51A mutation types have been identified, primarily including tandem repeat insertions in the promoter region and point mutations in the coding sequence. Among promoter tandem repeats, TR34/L98H and TR46/Y121F/T289A represent the two major subtypes.60 The TR34/L98H mutation increases the number of SrbA transcription factor binding sites in the promoter, thereby upregulating cyp51A expression and conferring cross-resistance to itraconazole and voriconazole.61 This mutation is closely linked to the widespread agricultural use of azole fungicides and is considered a signature of environmentally acquired resistance in A. fumigatus. The TR46/Y121F/T289A mutation primarily reduces voriconazole susceptibility and is also detected in highly resistant strains.10,62 Notably, the prevalence of these two major tandem repeat mutations is rising in both environmental and clinical isolates globally, highlighting the public health burden posed by the continuous influx of resistant strains from environmental reservoirs into clinical settings. Functional studies further reveal a key 34 bp core sequence within the tandem repeats that mediates regulatory effects. This region contains binding sites for SrbA, AtrR, the CCAAT-binding complex (CBC), and HapX. SrbA and AtrR are required for iron-independent activation of cyp51A, and repeated copies of the motif in resistant strains ensure efficient transcription. The CBC-HapX module mediates iron-dependent regulation. Notably, in vitro deletion of the HapX binding site relieves cyp51A repression and increases resistance independent of iron levels, whereas disruption of the CBC binding site reduces gene expression and enhances drug susceptibility.63 This finding suggests that fluctuating iron concentrations in the host pulmonary microenvironment may dynamically modulate azole resistance phenotypes in A. fumigatus via this regulatory module. Unlike promoter region mutations, point mutations in the coding sequence directly alter the structure of the Cyp51A protein. Amino acid substitutions at positions such as G54, G138, M220, and G448 can confer significant triazole resistance in A. fumigatus.10 These mutations may result in either high-level resistance to a single agent or cross-resistance to multiple azoles, thereby reducing overall triazole susceptibility.64 Different mutations are often associated with distinct cross-resistance profiles. For instance, the G54 mutation, which emerges during prolonged itraconazole therapy, elevates the minimum inhibitory concentration (MIC) of both itraconazole and posaconazole.15,16 The G138 mutation, such as G138S, can confer dual resistance to itraconazole and voriconazole. The G448 mutation, such as G448S, primarily induces voriconazole resistance while also reducing susceptibility to itraconazole and posaconazole.15 The correlation between specific mutations and cross-resistance profiles suggests that knowledge of a patient’s azole exposure history may help predict the likely resistance mutations, thereby informing empirical adjustments to antifungal therapy. Beyond structural alterations, overexpression of cyp51A constitutes another major resistance mechanism. This process involves increased enzyme production rather than changes in enzyme structure.65 Regulation is primarily mediated by the sterol response element in the promoter region and its associated transcription factors.3,66 In addition to tandem repeat insertions that amplify sterol response elements, disruptions in regulatory pathways may also induce overexpression. For example, the P88L mutation in hapE reduces repression by the CCAAT binding complex, leading to increased cyp51A expression and enhanced triazole resistance.62 Nevertheless, the relative contribution of cyp51A overexpression versus target-site mutations to clinical treatment failure remains unclear, and the upstream signaling pathways governing its expression have yet to be fully elucidated. Beyond alterations directly involving cyp51A, additional resistance mechanisms have been identified that extend the complexity of azole resistance. In addition to cyp51A, its paralog cyp51B also contributes to triazole resistance. cyp51B shares 59.4% sequence identity with cyp51A. Although often overlooked due to its low basal expression, cyp51B is a functional azole target; its expression is inducible under drug stress, and gene deletion studies confirm that strains lacking cyp51B exhibit increased azole susceptibility. A key example of its clinical relevance is isolate CM9640, which exhibits a pan-triazole-resistant phenotype. This strain harbors a novel G457S mutation in Cyp51B alongside an F390L mutation in Hmg1, a combination believed to drive the high-level resistance.67 This case illustrates that A. fumigatus can gradually accumulate resistance by combining mutations in multiple non-core targets, thereby increasing the complexity of clinical prediction. With the advancement of research, an increasing number of triazole resistance mechanisms independent of the cyp51 gene have been identified. Relevant mutated genes include hmg1, which encodes HMG-CoA reductase,68 as well as cox10 and cox7c, which encode components of cytochrome c oxidase.69–71 These mutations mediate resistance by disrupting either the sterol biosynthesis pathway or the heme biosynthesis pathway. The hmg1 gene encodes a key enzyme in the ergosterol biosynthetic pathway. Recent studies have shown that mutations in hmg1, particularly those located within the sterol-sensing domain, represent a novel azole resistance mechanism in A. fumigatus72 and are associated with acquired resistance during long-term therapy.73 However, many details underlying hmg1-mediated resistance remain unclear. Alterations in the cytochrome c oxidase system can also affect azole susceptibility. The R243Q substitution in A. fumigatus Cox10 enhances itraconazole resistance,71 whereas deletion or mutation of cox7c contributes to resistance by reducing intracellular drug accumulation and decreasing reactive oxygen species production.70 In addition to the aforementioned metabolic pathway abnormalities, imbalances in mitochondrial redox homeostasis also contribute to the development of resistance. Knockout of the FADB gene increases the susceptibility of A. fumigatus to posaconazole;74 FADB encodes an enzyme involved in cellular redox regulation and mitochondrial homeostasis. It has been hypothesized that FADB deletion may activate the HOG pathway, thereby enhancing the sensitivity of the fungus to oxidative stress.75 However, this hypothesis has not yet been experimentally confirmed. The emergence of these non-classical resistance mechanisms indicates that, beyond target-site mutations, genes governing fundamental cellular metabolism and stress responses constitute an important genetic background for the resistance phenotype. Prolonged antifungal therapy may exert selective pressure on A. fumigatus through multiple metabolic pathways. Taken together, these diverse molecular mechanisms underscore a fundamental principle: azole resistance is not a static phenotype but a dynamic evolutionary process shaped by both vertical mutation and horizontal gene transfer. In summary, although azoles exert a strong selective pressure that suppresses susceptible strains and enriches pre-existing resistance mutations,76 resistance evolution is not restricted to this mechanism alone. A study in 2022 confirmed that A. fumigatus can also acquire cyp51A-mediated resistance through horizontal gene transfer (HGT), a process that can be activated by single azole pressure or hypoxic environments but is constrained by the genetic background between strains.77,78 Therefore, the current understanding is that azole resistance represents a dynamic evolutionary process involving vertical mutation, horizontal transfer, and polygenic coordinated adaptation. This implies that focusing solely on the mutation spectrum of cyp51A is no longer sufficient to comprehensively assess the resistance risk of clinical isolates. Integrating genome-wide surveillance with functional resistance testing will be an inevitable trend in the future. Overexpression of the Drug Efflux Pump A. fumigatus reduces intracellular triazole concentrations by overexpressing efflux pump genes, representing one of the key mechanisms of azole resistance (Figure 4B). This overexpression is closely associated with gene amplification, promoter region mutations (such as in AfuMDR3 and AfuMDR4), and altered functions of transcriptional regulators.64 Efflux pumps in A. fumigatus primarily belong to the ATP-binding cassette (ABC) superfamily and the major facilitator superfamily (MFS).10,79 Although the A. fumigatus genome is predicted to contain over 300 efflux pump genes, only a small fraction are activated upon azole exposure.62 To date, six overexpressed genes have been definitively linked to resistance, including abcA, abcC, atrF, atrI, mdrA, and mdr1. Individual knockout of these genes in susceptible strains increases azole susceptibility.62,80,81 However, the independent contribution of efflux pump overexpression to clinical azole resistance remains difficult to quantify precisely. For instance, Fraczek et al82 observed marked overexpression of the ABC transporter gene cdr1B (abcC) in itraconazole-resistant clinical isolates lacking cyp51A mutations, implicating efflux pumps in target-independent resistance. Knockout of cdr1B increased susceptibility to multiple azoles, confirming its role in azole responsiveness. However, deletion of cdr1B in the resistant isolate F20063 only partially restored itraconazole susceptibility without fully reversing resistance, indicating that cdr1B overexpression contributes importantly, but not exclusively, to non-cyp51A-mediated resistance.82 This case illustrates that even when overexpression of a specific efflux pump is identified, its net contribution to the overall resistance phenotype remains difficult to disentangle from coexisting mechanisms. Furthermore, the feasibility of targeting efflux pumps therapeutically warrants cautious evaluation, given that mammalian cells also express ABC transporters. The regulatory pathways governing efflux pumps exhibit extensive crosstalk with other resistance mechanisms. The zinc-cluster transcription factor AtrR serves as a central node in this regulatory network. Functionally analogous to the pleiotropic drug resistance regulator Pdr1 in Saccharomyces cerevisiae, AtrR positively regulates both the target enzyme gene cyp51A and the ABC transporter gene abcC. Deletion of atrR results in markedly reduced expression of both genes.10,62 In addition, the C6 zinc finger transcription factor CTF1 acts as a negative regulator. Deletion of ctf1 upregulates mdr1, mdr2, and mdr4 and increases membrane ergosterol content, which together reduce azole susceptibility.83 Mitochondrial function also participates in this regulation. Mutations in the respiratory chain-associated protein Bcs1A can upregulate multiple efflux pump genes, an effect that is partially dependent on mdr1.84 However, whether this regulatory network is broadly activated in clinically resistant isolates and whether the degree of activation directly correlates with resistance levels remains insufficiently supported by current evidence. In summary, efflux pump overexpression drives multidrug resistance in A. fumigatus through regulatory networks centered on AtrR that also interact with mechanisms such as cyp51A expression. However, the development of drugs directly targeting fungal efflux pumps has long been constrained by issues of selective toxicity, and no fungal efflux pump inhibitor has yet entered clinical use. Future efforts should therefore focus on identifying fungal‑specific efflux pump inhibitors or on indirect strategies that target upstream regulators, thereby overcoming efflux‑mediated resistance while circumventing host toxicity. Biofilm-Associated Resistance Mechanism A. fumigatus biofilms constitute an important physical barrier and physiological adaptation underlying azole resistance.85,86 This three-dimensional structure is composed of hyphae, spores, and an extracellular matrix (ECM) rich in galactosaminogalactan (GAG), proteins, and polysaccharides.85 The development of biofilm-associated resistance is not attributable to a single mechanism but rather results from the combined effects of structural obstruction, physiological adaptation, and metabolic reprogramming. The development of A. fumigatus biofilms proceeds through three distinct stages, including initial, immature, and mature phases, with resistance increasing progressively at each stage (Figure 4C).87 In the initial stage, the biofilm exhibits a simple architecture with limited ECM secretion and remains relatively susceptible to antifungal agents. After approximately 12 hours, the biofilm enters the immature stage, characterized by the formation of a hyphal monolayer with increased ECM production and altered cell wall composition. During this stage, the multidrug resistance gene mdr4 is markedly upregulated at the transcriptional level, driving efflux pump overexpression and initiating the progressive enhancement of resistance.87,88 After 24 hours, the biofilm reaches maturity, marked by substantial ECM accumulation and the establishment of pronounced oxygen and nutrient gradients, leading to a significant increase in drug resistance. These observations indicate that the therapeutic window for clinical intervention is narrow. Once the biofilm enters the mature stage, conventional drug concentrations may become insufficient to control the infection. Mature biofilms exhibit a pronounced oxygen concentration gradient, and the hypoxic microenvironment is associated with a metabolic shift toward ethanol and butanediol fermentation. Transcriptomic analyses have confirmed that this process is regulated by the transcription factor silG. Deletion of silG leads to reduced biofilm biomass at late stages, suggesting a role for this gene in biofilm development and potentially in linking hypoxic adaptation to biofilm integrity.89 Concurrently, cell wall remodeling that occurs during biofilm formation, such as protein glycosylation, enhances interhyphal adhesion and further reduces drug permeability.87 Together, these structural and metabolic adaptations form the basis for the high-level drug resistance characteristic of mature biofilms. In summary, biofilm-associated resistance in A. fumigatus results from the coordinated action of three mechanisms, namely structural barriers, physiological adaptation, and metabolic reprogramming, which unfold along a temporal axis. The extracellular matrix provides immediate physical protection, efflux pump overexpression initiates active drug clearance during the immature stage, and metabolic heterogeneity in the mature phase confers sustained tolerance to the fungal population. This multistage and multilayered defense system implies that single-target antibiofilm strategies are unlikely to achieve comprehensive efficacy. Combined approaches that simultaneously target extracellular matrix synthesis, metabolic adaptation, and cell wall remodeling pathways may represent a more feasible direction for overcoming biofilm-associated treatment failure. For instance, small molecule inhibitors targeting the GAG deacetylase Agd3,90 such as imatinib lack direct antifungal activity yet can markedly weaken the protective barrier of A. fumigatus by inhibiting biofilm formation, thereby restoring the susceptibility of drug-resistant strains to azoles and reducing fungal virulence in insect infection models. Mechanisms of Triazole Adaptation and Resistance in A. fumigatus: The Role of Key Signaling Pathways Azole resistance in A. fumigatus is also closely linked to adaptive stress responses. Azole exposure triggers stress, activating evolutionarily conserved signaling pathways that coordinately drive fungal adaptation and resistance emergence (Figure 4D). Cell membrane stress in A. fumigatus is sensed by membrane proteins, including AfWsc1/3 and AfMidA, which initiate the cell wall integrity (CWI) pathway.91 This signaling cascade, including AfRom2, AfRho1, and AfPkcA, drives transcriptional reprogramming and cell wall reinforcement.91 Simultaneously, the high-osmolarity glycerol (HOG) pathway is activated; studies have shown that itraconazole stress upregulates the MAPK homologue SakA and glycerol synthesis genes such as gfdA and gppA. The calcineurin pathway also plays a key role: azole-induced increases in intracellular Ca2⁺ activate calcineurin, which dephosphorylates the transcription factor CrzA, promoting its nuclear translocation and regulating genes critical for cell wall and membrane homeostasis. This pathway is highly dependent on the molecular chaperone Hsp90, which stabilizes calcineurin and other client proteins, forming a central regulatory axis for azole tolerance. Hsp90 function is modulated by post-translational modifications; notably, lysine deacetylation, one such critical modification, is essential for its role in mediating resistance to voriconazole and caspofungin. Beyond these core pathways, emerging evidence implicates the target of rapamycin (TOR) kinase pathway, particularly the TORC2 complex, which influences azole susceptibility by regulating sphingolipid biosynthesis.91 In summary, azole resistance in A. fumigatus arises from a coordinated defense network rather than the simple sum of isolated pathways. Hsp90 serves as a molecular chaperone that stabilizes key proteins across multiple pathways, thereby constituting a central regulatory hub and representing an attractive target for simultaneously attenuating several resistance mechanisms. However, owing to the high conservation of these pathways between fungi and host cells, direct inhibition of their core components poses a significant risk of host toxicity.92 Future efforts should therefore focus on identifying fungal-specific regulatory targets or exploiting the compensatory crosstalk between pathways, thereby enabling coordinated suppression of the resistance network while minimizing host toxicity. Environmental and Animal Drivers of Drug Resistance Agricultural triazoles share an identical molecular target, cyp51A, with clinical triazoles; both classes degrade slowly in the environment and create persistent sub-inhibitory selective pressure.93,94 Approximately 30000 metric tons of agricultural azoles are applied annually across the EU and China, as documented in a 2024 One Health review by Williams et al16 A 2025 European Food Safety Authority (EFSA) risk assessment ranks the Netherlands and Germany first and second in fungicide application density per unit area, with Germany and France recording the highest total sales volumes, followed by Romania.95 2021 single-year data indicate non-medical triazole sales in the EU are approximately 1000-fold greater than human systemic triazole consumption.95 These agrochemicals persist in soil with strong mobility; propiconazole, for instance, has a soil half-life of up to 300 days and disperses broadly via aerosol drift and farmland runoff.16 The widespread distribution of A. fumigatus in soil and humus, combined with the massive annual input and long environmental persistence of agricultural azoles, establishes a near-continuous sub-inhibitory selection regime—one far broader in both time and space than the selective pressure arising from clinical antifungal administration. In intensive agricultural regions without targeted azole regulation, environmental azole-resistant A. fumigatus (ARAF) has been widely detected. Surveillance in Yunnan greenhouses revealed an overall resistance rate of nearly 80%, with over 30% of isolates cross-resistant to itraconazole and voriconazole—the highest reported in agricultural environments to date.7 The frequency of cyp51A promoter tandem repeat mutations varied markedly across greenhouses (0–40%), with TR34/L98H, TR46/Y121F/T289A, and TR53 identified as the dominant environmental haplotypes, suggesting that differences in management practices or environmental conditions may influence the local enrichment of resistant clones.7 Compared with clinical isolates, TR34/L98H was more abundant in environmental samples, whereas many multidrug-resistant isolates carried wild-type cyp51A, indicating that TR-targeted screening alone is insufficient, and broader diagnostic targets are needed.96 The absence of rainfall leaching in greenhouses leads to long-term accumulation of triadimefon, tebuconazole and difenoconazole in soil, generating sustained sub-inhibitory selective pressure7—this closed environment may serve as an in situ evolution chamber for resistance selection, a scenario fundamentally distinct from open-field agriculture. Multiple agricultural–environmental–clinical sampling studies have provided robust evidence for environmental-to-human transmission of ARAF. International horticultural bulb trade constitutes a major vector for intercontinental clone dissemination. Uehara et al8 detected cyp51A tandem repeat mutations in 51.7% of isolates from locally bred Japanese tulip bulbs, and whole-genome sequencing (WGS) phylogenetic analysis confirmed high genetic homology to Dutch agricultural and clinical isolates.8 Snelders et al97 performed WGS on 157 isolates collected from Dutch resistance hotspots, water sources, and two hospitals, identifying five clonal clusters shared between environmental and patient isolates corresponding to six invasive aspergillosis cases.97 Notably, a TR34/L98H clonal cluster originating from a flower bulb waste hotspot matched three confirmed/probable azole-resistant cases, suggesting that agricultural waste hotspots can yield resistant clones highly homologous to clinical strains. Their integrated analysis of over 1200 publicly available genomes further revealed that TR34 and TR46 clonal genotypes circulate across the Netherlands, Germany, and the UK, with some clones shared transnationally.97 Epidemiological evidence of cross-regional ARAF dissemination has prompted EU policy attention. In 2025, the European Food Safety Authority (EFSA), the European Centre for Disease Prevention and Control (ECDC), the European Chemicals Agency (ECHA), the European Environment Agency (EEA), and the European Medicines Agency (EMA), with scientific support from the Joint Research Centre (JRC), issued a joint assessment concluding that agricultural azole use is likely or very likely to select for pathogenic ARAF, with a clear link between environmental azole exposure and clinical cross-resistance.95 The report recommends a cross-sectoral tiered risk assessment and surveillance framework, while acknowledging that the EU has not yet established a standardized transnational One Health surveillance programme specifically for azole-resistant Aspergillus. While the risk has been acknowledged, the absence of mandatory surveillance may limit the translation of environmental resistance data into clinical practice. Combined exposure to multiple agricultural fungicides may drive broader resistance profiles: TR-type cyp51A variants also tolerate benzimidazoles and quinone outside inhibitors (QoIs), so restricting triazoles alone cannot eliminate environmental resistance reservoirs.97 Moreover, the agricultural DHODH inhibitor ipflufenoquin (IFQ) shares the same target as the clinical drug olorofim; large-scale IFQ use may trigger cross-sectoral cross-resistance, mandating standardized One Health risk assessments before the launch of new agricultural fungicides.16 Beyond acquired resistance, adaptive phenotypic changes further enhance survival fitness under environmental stress. Field data from Ningxia, China, showed that TR34/L98H-carrying strains withstand both hyperosmotic and oxidative stress, suggesting remodeling of global stress-response pathways; this greatly improves fungal survival in both farmland and host microenvironments, complicating environmental decontamination and clinical therapy.98 The role of animals in the ARAF transmission cycle is increasingly recognized as a critical yet underappreciated One Health concern. Clinical manifestations vary by species: sinonasal aspergillosis predominates in dogs, whereas pulmonary and air-sac infections are the hallmarks in birds and poultry.9 Captive settings further amplify risk, as evidenced by penguin incidence rates of 3.4–8.6% and mortality up to 68%, alongside severe fungal lesions, predominantly caused by A. fumigatus, in approximately 15% of post-mortem harbour porpoises.99 Veterinary practice remains heavily reliant on itraconazole and voriconazole,99 yet the prolonged azole use necessitated by captive care inadvertently transforms companion animal and captive wildlife sectors into an independent resistance selection milieu—conceptually and epidemiologically distinct from human clinical environments. Detection of animal-derived ARAF has drawn increasing attention. Dieste-Pérez et al documented resistant isolates recovered from horses, companion animals, poultry and wildlife, with positivity rates of 0.5% to 31% among zoo specimens;100 TR34/L98H azole-resistant A. fumigatus were also isolated from penguin enclosures at a Belgian zoo and air samples from Madrid Zoo, Spain.101,102 Dutch surveillance data covering 2015–2020 provide further population-level evidence: 11.3% of animal isolates showed azole resistance, 81.3% of which carried agriculture-linked TR34/L98H. Notably, 71.4% of animals with complete medication records had no prior azole exposure.9 These animal-derived genotypes are highly homologous to agricultural and clinical isolates, and TR34/L98H predominates among animal strains. This pattern suggests that agricultural environments constitute the primary resistance reservoir. However, the possibility of bidirectional transmission between animals and environmental niches cannot be fully ruled out. In addition, these findings indicate that captive animal colonies may serve as sentinel bioindicators for environmental antifungal resistance pressure (Figure 4E). Prolonged veterinary azole treatment forms an independent resistance selection pathway. While 59% of veterinary antifungal literature addresses companion animals, total veterinary azole sales are far below agricultural volumes.6 French 2022 data show only 0.04% of companion animals receive oral azole-based antifungals.99 The fact that most resistant animal isolates have no prior azole exposure indicates veterinary use exerts weaker population-scale selective pressure than agricultural fungicides, though individual risks and insufficient surveillance deserve attention. To date, no whole-genome sequencing data have confirmed direct animal-to-human transmission of ARAF. In summary, agricultural azole use drives multidrug‑resistant A. fumigatus across environmental, animal, and clinical compartments. However, current surveillance remains clinically siloed and lacks systematic environmental and veterinary coverage. A coordinated One Health monitoring framework is urgently needed to track resistance across the entire transmission chain. Strategies for the Prevention and Control of Drug Resistance Novel Therapeutic Approaches Resistant strains from environmental and animal sources continuously enter clinical settings, steadily eroding the existing therapeutic arsenal of antifungal agents. To this end, the development of novel antifungals has recently been accelerated along three core research directions: targeting entirely novel pathways, optimizing existing drug structures, and exploring synergistic mechanisms (Table 1).Table 1Characteristics and Development of Novel Antifungal DrugsAntifungal Compound NameDrug StructureMechanismSpectrum & Resistance CoverageClinical Application ValueDevelopment StageSafety ProfileFormulation TypeOlorofim (F901318)OrotomideFungal DHODH inhibitor that blocks pyrimidine biosynthesis essential for nucleic-acid and cell-wall synthesisActive against filamentous/dimorphic fungi, including azole-resistant A. fumigatus with cyp51A mutationsOral agent for invasive aspergillosis, including azole‑resistant infectionsPhase III trial (OASIS) has completed and met its primary endpointPhase I: well tolerated; mild AEs (nausea, dizziness)Oral formulationIbrexafungerpTriterpenoidInhibits β-(1,3)-D-glucan synthase, disrupting fungal cell wall synthesisFungicidal against Candida spp.; fungistatic against Aspergillus spp.Approved for acute VVC; Active against MDR C. auris and Aspergillus spp.FDA-approved for VVC/RVVC; completed Phase III FURI (NCT03059992)Mild–moderate gastrointestinal adverse effects; avoid strong CYP3A4 inducersMarketed: oral formulation; Development: IV formulationRezafunginEchinocandinInhibits β-(1,3)-D-glucan synthase, disrupting cell wall integrityPotent activity against Candida spp.; active against Aspergillus spp. (including azole-resistant strains)Once-weekly dosing; candidemia/invasive candidiasis; potential IFD prophylaxisApproved for candidemia/invasive candidiasis; Phase III ReSPECT (prophylaxis) met primary endpointSafety; common AEs: mild chest discomfort, GI upset, flushing, myalgiaIV injectionFosmanogepixFirst-in-Class GPIAnchor InhibitorInhibits Gwt1, the GPI-anchored protein lossBroad-spectrum activity covering Candida, azole-resistant Aspergillus, Scedosporium, Fusarium, and endemic fungiActive against drug-resistantfungi anduncommon refractory moldsPhase II AEGIS trial (NCT04240886) terminated; Phase III trials ongoing for candidemia and invasive mold infections (NCT06925321)Well tolerated: mild transient headaches; safe in renal impairment without dose adjustmentAvailable as both IV and oral formulationsAM-2-19PolyeneSelectively extracts ergosterol from fungi; inert to human cholesterolBroad-spectrum activity against Candida, Aspergillus, and drug-resistant strainsLow nephrotoxicity; potential option for drug-resistant or severe fungal infectionsPhase II clinical trial (NCT07215273)Minimal renal toxicity. Nontoxic to various mammalian cell types; no hERG/genotoxicityReady-to-use DP2K micelle for IV injectionMBX-7591Nonspirocyclic piperidinePutatively inhibits fungal stearoyl-CoA Δ9-desaturase (SdeA), blocking oleic acid synthesis and disrupting the cell membraneHighly effective against A. fumigatus (including triazole-resistant strains) and Rhizopus spp., with significant synergy to triazolesTargeting drug-resistant strains and able to synergize with existing triazole drugsCurrently in the preclinical research stageNot reported in detail—T-2307ArylamidineDisrupts mitochondrial membrane potential, leading to fungal cell deathCovers Candida/Cryptococcus, including azole- and echinocandin-resistant strainsProvides a new mechanism for treating multidrug-resistant invasive candidiasis/cryptococcosisPreclinical studies and Phase I clinical trial completedClinical safety remains to be validated—ETD15144-amino-acid recombinant, amphiphilic antimicrobial peptideTargets fungal glucosylceramides (GlcCer), disrupting membrane integrityInhibits growth and metabolism of both azole-susceptible and azole-resistant A. fumigatusPromising candidate, especially for azole-resistant infections via nebulized inhalationPreclinical (cell and in vitro models)Non-cytotoxic to human bronchial epithelial cellsStudied in aqueous solution; suitable for nebulizationAbbreviations: AEs, adverse events; DHODH, dihydroorotate dehydrogenase; GI, gastrointestinal; GPI, glycosylphosphatidylinositol; IFD, invasive fungal disease; IV, intravenous; MDR, multidrug resistant; VVC, vulvovaginal candidiasis; RVVC, recurrent vulvovaginal candidiasis; FURI, Fungal Infection Refractory Investigation Trial; Em dashes (—) indicate information not available or not applicable. Table 1Characteristics and Development of Novel Antifungal DrugsAntifungal Compound NameDrug StructureMechanismSpectrum & Resistance CoverageClinical Application ValueDevelopment StageSafety ProfileFormulation TypeOlorofim (F901318)OrotomideFungal DHODH inhibitor that blocks pyrimidine biosynthesis essential for nucleic-acid and cell-wall synthesisActive against filamentous/dimorphic fungi, including azole-resistant A. fumigatus with cyp51A mutationsOral agent for invasive aspergillosis, including azole‑resistant infectionsPhase III trial (OASIS) has completed and met its primary endpointPhase I: well tolerated; mild AEs (nausea, dizziness)Oral formulationIbrexafungerpTriterpenoidInhibits β-(1,3)-D-glucan synthase, disrupting fungal cell wall synthesisFungicidal against Candida spp.; fungistatic against Aspergillus spp.Approved for acute VVC; Active against MDR C. auris and Aspergillus spp.FDA-approved for VVC/RVVC; completed Phase III FURI (NCT03059992)Mild–moderate gastrointestinal adverse effects; avoid strong CYP3A4 inducersMarketed: oral formulation; Development: IV formulationRezafunginEchinocandinInhibits β-(1,3)-D-glucan synthase, disrupting cell wall integrityPotent activity against Candida spp.; active against Aspergillus spp. (including azole-resistant strains)Once-weekly dosing; candidemia/invasive candidiasis; potential IFD prophylaxisApproved for candidemia/invasive candidiasis; Phase III ReSPECT (prophylaxis) met primary endpointSafety; common AEs: mild chest discomfort, GI upset, flushing, myalgiaIV injectionFosmanogepixFirst-in-Class GPIAnchor InhibitorInhibits Gwt1, the GPI-anchored protein lossBroad-spectrum activity covering Candida, azole-resistant Aspergillus, Scedosporium, Fusarium, and endemic fungiActive against drug-resistantfungi anduncommon refractory moldsPhase II AEGIS trial (NCT04240886) terminated; Phase III trials ongoing for candidemia and invasive mold infections (NCT06925321)Well tolerated: mild transient headaches; safe in renal impairment without dose adjustmentAvailable as both IV and oral formulationsAM-2-19PolyeneSelectively extracts ergosterol from fungi; inert to human cholesterolBroad-spectrum activity against Candida, Aspergillus, and drug-resistant strainsLow nephrotoxicity; potential option for drug-resistant or severe fungal infectionsPhase II clinical trial (NCT07215273)Minimal renal toxicity. Nontoxic to various mammalian cell types; no hERG/genotoxicityReady-to-use DP2K micelle for IV injectionMBX-7591Nonspirocyclic piperidinePutatively inhibits fungal stearoyl-CoA Δ9-desaturase (SdeA), blocking oleic acid synthesis and disrupting the cell membraneHighly effective against A. fumigatus (including triazole-resistant strains) and Rhizopus spp., with significant synergy to triazolesTargeting drug-resistant strains and able to synergize with existing triazole drugsCurrently in the preclinical research stageNot reported in detail—T-2307ArylamidineDisrupts mitochondrial membrane potential, leading to fungal cell deathCovers Candida/Cryptococcus, including azole- and echinocandin-resistant strainsProvides a new mechanism for treating multidrug-resistant invasive candidiasis/cryptococcosisPreclinical studies and Phase I clinical trial completedClinical safety remains to be validated—ETD15144-amino-acid recombinant, amphiphilic antimicrobial peptideTargets fungal glucosylceramides (GlcCer), disrupting membrane integrityInhibits growth and metabolism of both azole-susceptible and azole-resistant A. fumigatusPromising candidate, especially for azole-resistant infections via nebulized inhalationPreclinical (cell and in vitro models)Non-cytotoxic to human bronchial epithelial cellsStudied in aqueous solution; suitable for nebulizationAbbreviations: AEs, adverse events; DHODH, dihydroorotate dehydrogenase; GI, gastrointestinal; GPI, glycosylphosphatidylinositol; IFD, invasive fungal disease; IV, intravenous; MDR, multidrug resistant; VVC, vulvovaginal candidiasis; RVVC, recurrent vulvovaginal candidiasis; FURI, Fungal Infection Refractory Investigation Trial; Em dashes (—) indicate information not available or not applicable. Characteristics and Development of Novel Antifungal Drugs Abbreviations: AEs, adverse events; DHODH, dihydroorotate dehydrogenase; GI, gastrointestinal; GPI, glycosylphosphatidylinositol; IFD, invasive fungal disease; IV, intravenous; MDR, multidrug resistant; VVC, vulvovaginal candidiasis; RVVC, recurrent vulvovaginal candidiasis; FURI, Fungal Infection Refractory Investigation Trial; Em dashes (—) indicate information not available or not applicable. Drugs targeting novel pathways represent a fundamental strategy to circumvent existing resistance. The first-in-class orotomide Olorofim inhibits dihydroorotate dehydrogenase (DHODH), blocking pyrimidine synthesis, and shows exceptional activity against azole-resistant Aspergillus spp., with the pivotal Phase III OASIS trial (NCT05101187) having met its primary endpoint of non-inferiority, and regulatory submissions are now planned.73,103–105 Similarly, Fosmanogepix (FMGX) disrupts cell wall integrity by inhibiting the Gwt1 enzyme, interfering with glycosylphosphatidylinositol (GPI)-anchored protein biosynthesis via its active metabolite MGX. Effective against azole-resistant strains in vitro and in vivo, it is currently being evaluated in Phase III trials, including NCT06925321 for invasive mold infections, due to its unique, non-cross-resistant target.103,106 Structural optimization of existing drug classes aims to enhance efficacy and improve safety. AM-2-19, a structurally modified derivative of amphotericin B, retains potent ergosterol-targeting antifungal activity with significantly reduced nephrotoxicity, and has now entered Phase II clinical trials (NCT07215273), offering a promising “high-efficacy, low-toxicity” option for immunocompromised patients.103,107 Among echinocandins, rezafungin is a long-acting formulation with once-weekly dosing, improves patient compliance, and is approved for candidemia and invasive candidiasis. Its Phase III ReSPECT trial (NCT04368559) for prophylaxis in allogeneic HSCT recipients has met its primary endpoint with positive results, and regulatory submissions are anticipated in 2026.106,108,109 Although its resistance mechanism is primarily associated with FKS mutations, its high efficacy may help delay resistance emergence.108,110 Ibrexafungerp, the first oral glucan synthase inhibitor, circumvents FKS-mediated resistance by targeting a unique binding site.105,109 It exhibits broad-spectrum in vitro activity against Aspergillus spp., including resistant strains; however, further studies are needed to evaluate its clinical efficacy and establish susceptibility breakpoints.111,112 Exploring synergistic effects and unique mechanisms represents another significant direction. MBX-7591 disrupts membrane integrity by reducing oleic acid content and increasing membrane saturation, showing efficacy against triazole-resistant A. fumigatus and synergy with triazoles.113,114 T-2307 exerts fungicidal activity by accumulating in fungal mitochondria and disrupting membrane potential; however, its additional effects on A. fumigatus, such as biofilm inhibition, require further experimental validation.103,115 The synthetic antimicrobial peptide ETD151 targets the conserved membrane sphingolipid glucosylceramide (GlcCer), potently inhibiting both azole-susceptible and azole-resistant strains without inducing resistance after repeated passaging. In a human airway epithelial model, it retained antifungal activity without cytotoxicity and showed additivity with caspofungin. Its conserved target, low resistance propensity, and suitability for nebulization position it as a promising inhaled candidate for chronic pulmonary aspergillosis, though in vivo efficacy and safety require further validation.116 In summary, novel targets, optimized structures, long-acting oral formulations, and combination therapies are expanding options against A. fumigatus resistance. From in vitro activity to clinical efficacy, these agents still face critical steps that must be overcome, including phase III trial validation, the establishment of susceptibility breakpoints, and the identification of appropriate patient populations. The results of clinical trials in the coming years will determine their ultimate role in the treatment of drug-resistant A. fumigatus infections. Targeted Drug Delivery Traditional antifungals often face the dilemma of insufficient local concentration versus systemic toxicity.117,118 Targeted delivery technologies address this by precisely transporting drugs to the infection site.118 For example, DEC-AmB-LLs liposomes targeting the Dectin-1 receptor showed significantly higher in vitro antifungal activity against A. fumigatus than untargeted controls.117,119 Similarly, Dectin-2-directed liposomes demonstrated potent in vitro activity without increased toxicity to human cells.119 Thus, targeted delivery optimizes drug biodistribution, improving antifungal efficacy while reducing adverse effects. However, key challenges remain for clinical translation, including optimizing target specificity, ensuring in vivo carrier stability, and establishing scalable production protocols. Immunomodulation Immunomodulation is not an independent antifungal therapy but rather an important adjunctive strategy. In immunocompromised patients, the immune system is often unable to effectively clear the pathogen, and antifungal agents alone frequently yield limited efficacy.109 This is precisely where the value of immunomodulatory intervention lies. Significant progress has been made in T-cell-based immunotherapy. Genetically engineered A. fumigatus-specific chimeric antigen receptor (Af-CAR) T cells, particularly the CD8⁺ subset, can directly recognize and damage fungal hyphae in vitro. In an immunodeficient mouse model of invasive pulmonary aspergillosis, adoptive transfer of CD8⁺ Af-CAR T cells significantly reduced pulmonary fungal burden and improved survival.120 Recent in vitro studies further show that Vγ9Vδ2 T cells exert direct antifungal activity against hyphal forms of multiple filamentous fungi, including A. fumigatus. This activity, preserved in tested azole-resistant strains, depends on direct cell-hyphae contact and calcium-mediated degranulation.121 Together, these approaches exemplify the vital adjunctive role of immune modulation. Dendritic-cell-based strategies also show promise. Immunization with Asp f16-sensitized dendritic cells combined with adjuvants effectively induces a Th1-dominant immune response, conferring resistance to Aspergillus infection.122 Preliminary observations suggest that adding this approach to antifungal therapy may benefit patients. Mechanistically, within the immunosuppressive milieu created by calcineurin inhibitors, IFN-γ reverses dendritic cell suppression and restores Th1-polarizing capacity by promoting epigenetic remodeling that favors STAT1-over STAT3-mediated signaling.46 Overall, current immunomodulatory strategies involve the direct supplementation of effector cells with antifungal activity and the restoration of host immunoregulatory function to reestablish protective immunity. Among these approaches, only IFN‑γ is under clinical evaluation (NCT05653193), whereas Af‑CAR T cells, Vγ9Vδ2 T cells, and dendritic cell‑based strategies remain at preclinical stages, warranting further translational studies. Conclusion The resistance of A. fumigatus to azole antifungals and its pathogenic mechanisms are not independent processes. Under the selective pressure imposed by the host immune gradient, pathogenic features such as biofilm barrier formation, metabolic reprogramming, and immune evasion simultaneously provide a temporal window and a protected niche for the accumulation of resistance mutations and the overexpression of efflux pumps. Conversely, the cross-stress tolerance acquired by resistant strains under drug pressure further enhances their persistence in both the host and the environment. This mutual reinforcement between pathogenicity and resistance is particularly pronounced in severely immunocompromised patients and represents a central cause of refractory infections. Current research has achieved progress in the following areas: multiple resistance mechanisms have been elucidated, with cyp51A mutations representing the core component, and the molecular basis of efflux pump regulatory networks and biofilm-associated resistance has been preliminarily characterized. Moreover, the role of agricultural azole fungicides as an environmental reservoir for the selection of clinically resistant strains has been confirmed. Therapeutically, novel agents targeting distinct pathways, such as olorofim and fosmanogepix, together with immunomodulatory strategies including Af-CAR T cells, have demonstrated potential to overcome resistance in experimental models. Nevertheless, several critical issues remain unresolved. Mechanistically, the regulatory details of resistance pathways, the synergistic networks linking resistance and virulence genes, and the actual contribution of horizontal gene transfer to the clinical evolution of resistance require further elucidation. Therapeutically, the clinical positioning of novel targeted agents and immunomodulatory strategies awaits confirmation in phase III trials, and breakthroughs are still needed in the in vivo stability and large-scale production of targeted drug delivery systems. From a public health perspective, effectively translating environmental resistance surveillance data into clinical decision-making remains a central challenge for the implementation of the One Health framework. In summary, tackling triazole resistance in A. fumigatus demands a unified One Health perspective integrating fungal genetics, host immune context, and environmental selective pressures. Of the three dimensions, systematic environmental surveillance of agricultural and veterinary fungal reservoirs stands as the most feasible near-term research priority to block cross-sector transmission of resistant strains, with deeper exploration of fungal genetic variants and host immunomodulatory therapies as subsequent key research directions. Ultimately, breakthroughs will depend on targeted, coordinated interventions that simultaneously address all three interconnected layers.